Saturday, December 3, 2022

561.316.3330

Biotechnology News Magazine

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Expanded portfolio includes sustainability-minded hanging labels for infusion bottles, and labels for autoinjector pens

Latest Posts

Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 1 Study of Bomedemstat in Combination with Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia

Venetoclax is a BCL-2 inhibitor approved by the U.S. Food and Drug Administration (FDA) for treatment of several hematologic cancers, including in combination with azacytidine for elderly patients with AML unable to tolerate the standard of care.

Acer Therapeutics Announces $1.5M Private Placement

The proceeds from the private placement will be used by Acer Therapeutics for working capital and general corporate purposes and, together with Acer’s existing cash and cash equivalents, are expected to be sufficient to fund the Company’s anticipated operating and capital requirements through the fourth quarter of 2022.

AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “The selection of ACI-35.030 for further development is a significant step for this collaboration. Early clinical testing showed that ACI-35.030 was generally well tolerated and induced specific activity against the pathological species of Tau, including the neurotoxic pTau and enriched paired helical filaments (ePHF) species, both of which are closely implicated in Alzheimer’s disease (AD).

TransCode Therapeutics Announces eIND Submission to US FDA for Planned First-in-Human Clinical Trial in Patients with Advanced Solid Tumors

The planned clinical trial is to evaluate TransCode’s lead therapeutic candidate, TTX-MC138, in cancer patients with advanced solid tumors. ​TTX-MC138 is designed to inhibit the pro-metastatic RNA, microRNA-10b, described as the master regulator of metastasis in a number of advanced solid tumors. TransCode Therapeutics believes that TTX-MC138 could be used as a treatment for many of these cancers.

Schreiner MediPharm, a Germany-based global provider of innovative functional label solutions for the healthcare industry, will debut sustainability-minded versions of two popular products at Pack Expo, October 23-26 in Chicago. At Booth W-15047, the company will showcase a pair of label solutions designed via three key sustainability considerations: recycled/renewable materials, sorted recycling/disassembling, and CO2 emissions reduction.

Pharma-Tac hanger label
The Pharma-Tac hanger label has continuously been extended by diverse variants and features and can now also be produced using environmentally friendly film material.

The new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions. For example, one of the items on display at Pack Expo will be a more sustainable version of its Pharma-Tac label for infusion bottles with integrated hanger and removable documentation parts. A more eco-friendly version of Schreiner MediPharm’s Autoinjector-Label – featuring its popular anti-slip functionality – also will be showcased. For both new product solutions, the company utilized film materials that are either recycled or produced from renewable raw materials.

Autoinjectors are used for easy self-medication. The marking label made of environmentally friendly material can be equipped with individually combinable functions.
Autoinjectors are used for easy self-medication. The marking label made of environmentally friendly material can be equipped with individually combinable functions.

To demonstrate that the more sustainable materials perform as well and reliably as conventional substrates, the in-house R&D team conducted a series of extensive tests. For example, the Pharma-Tac label was subjected to load and gravitational trials, and both the hanger label and Autoinjector-Label underwent testing for adhesion, ink adhesion, print durability and laser marking viability. All tests were passed flawlessly.

In addition, a Product Carbon Footprint (PFC) was calculated for each of the new sustainable label concepts. This calculation considers the CO2 emissions of a product from raw materials through manufacturing to delivery – referred to as “cradle-to-gate” analysis – as well as end-of-life scenarios, or so-called “cradle-to-grave” impact.

Based on the findings, and using the materials that have been qualified, Schreiner MediPharm is able to design and develop customized labeling solutions that can contribute to a more sustainable pharma supply chain.

“The healthcare industry faces steeper challenges to sustainability than the vast majority of other sectors, since the safety of patients and efficacy of drugs must take priority on a more mission-critical scale,” said Gene Dul, President of Schreiner MediPharm US. “The sustainability-minded labels we’ll be showing at Pack Expo exmplify our commitment to reducing the environmental impact without sacrificing patient-centricity in the slightest. It’s an important step toward a more circular healthcare economy.”

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine